Spots Global Cancer Trial Database for 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Official Title: 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Study ID: NCT01370330
Conditions
Interventions
Study Description
Brief Summary: This is a compassionate use protocol to allow patients with advanced neuroblastoma palliative access to 131I-metaiodobenzylguanidine (131I-MIBG).
Detailed Description: Neuroblastoma remains a fatal disease for a large percentage of patients, especially those with high-risk disease features who become resistant to conventional therapy. 131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma. 131I-MIBG is active against relapsed or refractory neuroblastoma and associated hematopoietic toxicity can be abrogated with autologous stem cell rescue. 131I-MIBG given in doses of 10-18 millicurie (mCi)/kg with stem cell rescue, if necessary, is safe and effective palliative therapy for refractory or relapsed neuroblastoma patients.
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, San Francisco, San Francisco, California, United States
Contact Details
Name: Kieuhoa Vo, MD
Affiliation: University of California, San Francisco
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
